Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2007 Jun 28;13(24):3316-22.
doi: 10.3748/wjg.v13.i24.3316.

Therapeutic procedures for submucosal tumors in the gastrointestinal tract

Affiliations
Review

Therapeutic procedures for submucosal tumors in the gastrointestinal tract

Laura-Graves Ponsaing et al. World J Gastroenterol. .

Abstract

This review is part three of three and will present an update on the therapeutic options and procedures concerning gastrointestinal (GI) submucosal tumors (SMTs). The aim of this paper is to investigate the treatments of GI SMTs and to present a case of a gastrointestinal stromal tumor (GIST). Literature searches were performed to find information on therapy for GI SMTs. Based on these searches, the optimal therapeutic procedures could be outlined. The choice of treatment of localized tumors is endoscopic resection if possible or, alternatively, laparoscopic resection or surgical resection by an open procedure. However, benign SMTs should only be excised if symptoms are present, and GISTs should be treated with particular precautions. Irresectable or recurrent GISTs may be successfully treated with the tyrosine kinase inhibitor, imatinib.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Histological findings of the gastrointestinal stromal tumor described in the case are presented showing spindle shaped cells with mild, nuclear atypia, few mitoses and slight, diffuse lymphocyte infiltration is seen (HE, x 100). Courtesy of B. Vainer.
Figure 2
Figure 2
Histological findings of the gastrointestinal tumor described in the case are presented showing a positive CD34 immunoreaction (x 100). Courtesy of B. Vainer.
Figure 3
Figure 3
Histological findings of the gastrointestinal stromal tumor described in the case are presented showing a positive CD117 immunoreaction (x 200). Courtesy of B. Vainer.

Similar articles

Cited by

References

    1. Shim CS, Jung IS. Endoscopic removal of submucosal tumors: preprocedure diagnosis, technical options, and results. Endoscopy. 2005;37:646–654. - PubMed
    1. Blay JY, Bonvalot S, Casali P, Choi H, Debiec-Richter M, Dei Tos AP, Emile JF, Gronchi A, Hogendoorn PC, Joensuu H, et al. Consensus meeting for the management of gastrointestinal stromal tumors. Report of the GIST Consensus Conference of 20-21 March 2004, under the auspices of ESMO. Ann Oncol. 2005;16:566–578. - PubMed
    1. Gill SS, Heuman DM, Mihas AA. Small intestinal neoplasms. J Clin Gastroenterol. 2001;33:267–282. - PubMed
    1. Miettinen M, El-Rifai W, H L Sobin L, Lasota J. Evaluation of malignancy and prognosis of gastrointestinal stromal tumors: a review. Hum Pathol. 2002;33:478–483. - PubMed
    1. Fletcher CD, Berman JJ, Corless C, Gorstein F, Lasota J, Longley BJ, Miettinen M, O'Leary TJ, Remotti H, Rubin BP, et al. Diagnosis of gastrointestinal stromal tumors: A consensus approach. Hum Pathol. 2002;33:459–465. - PubMed